How much weight can I expect to lose on semaglutide or tirzepatide?

Clinical trial data suggest semaglutide 2.4 mg may support approximately 14.9% average body weight reduction over 68 weeks (STEP 1 trial, PMID: 33567185). Tirzepatide at the 15 mg dose produced a mean 20.9% weight loss over 72 weeks in the SURMOUNT-1 trial (PMID: 35658024). Individual results vary significantly based on adherence, lifestyle, starting metabolic health, and genetic factors. These are population averages, not guarantees.

Will I regain weight if I stop taking GLP-1 medications?

Evidence from the STEP 1 extension study and SURMOUNT-4 trial indicates that approximately two-thirds of lost weight is typically regained within 12 months of discontinuing treatment. This reflects the chronic disease model of obesity management — ongoing treatment is generally required to maintain benefits, similar to blood pressure or cholesterol medications. Weight regain upon discontinuation is a pharmacological consequence, not a treatment failure.

Are these medications safe long-term?

The SELECT trial followed non-diabetic patients for approximately 40 months with a favorable safety profile and demonstrated a 20% reduction in major cardiovascular events (PMID: 37952131). Long-term safety data beyond 5 years are still accumulating. Both medications carry real risk profiles including absolute contraindications (personal or family history of medullary thyroid carcinoma, MEN2) and important cautions (pancreatitis history, diabetic retinopathy, gastroparesis). These are prescription medications requiring clinician evaluation and ongoing monitoring.

Is compounded semaglutide still available in 2026?

The FDA declared the semaglutide shortage resolved in February 2025, ending the broad legal basis for compounding essentially equivalent copies of Ozempic or Wegovy. Compounded semaglutide under 503A pharmacies remains legally permissible only under specific, documented conditions — including a prescriber-documented allergy to a brand-product excipient, need for a dose not commercially available, or a clinically justified combination formulation. Cost savings and patient preference alone are not qualifying reasons under federal law.

What happens if I experience nausea?

Nausea is the most common adverse effect, typically most pronounced during dose escalation. Eating smaller, lower-fat meals; staying hydrated; and taking medication at a consistent time may help. Persistent or severe nausea should be discussed with your prescribing clinician — dose adjustments or slower titration schedules are often available. Most patients find nausea substantially improves after the initial weeks of a given dose.

Can I use these medications if I have type 2 diabetes?

GLP-1 receptor agonists are FDA-approved and widely used in type 2 diabetes management. Whether semaglutide or tirzepatide is appropriate for you depends on your complete medication list, kidney function, cardiac history, HbA1c, and clinical goals — all matters to discuss with your prescribing clinician. These agents do not independently cause hypoglycemia, but interactions with other glucose-lowering medications require clinical evaluation.

GLP-1 Receptor Agonists: Semaglutide & Tirzepatide

Mechanism of action

What they are and how they work.

Glucagon-like peptide-1 (GLP-1) receptor agonists mimic the action of naturally occurring incretin hormones secreted by the small intestine in response to food. GLP-1 is a "fullness signal" your gut normally releases after eating; these medications extend and amplify that signal pharmacologically.

Semaglutide — GLP-1 Receptor Agonist

Semaglutide (brand names Ozempic® for diabetes, Wegovy® for obesity, Rybelsus® oral for diabetes) is a GLP-1 receptor agonist developed by Novo Nordisk. It binds to and activates GLP-1 receptors in the pancreas, brain, gut, and cardiovascular system. Key actions include: (1) glucose-dependent stimulation of insulin secretion; (2) suppression of glucagon; (3) slowing of gastric emptying; and (4) activation of hypothalamic satiety centers that reduce appetite and caloric intake. It is not insulin and does not independently cause hypoglycemia.

Tirzepatide — Dual GIP/GLP-1 Receptor Agonist

Tirzepatide (Mounjaro® for diabetes, Zepbound® for obesity, Eli Lilly) is the first approved dual GIP/GLP-1 receptor agonist. It simultaneously activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors. This dual mechanism appears to produce greater weight loss than GLP-1 agonism alone, as GIP receptors are expressed in adipose tissue and influence lipid metabolism independently of the GLP-1 pathway. Both agents are administered as once-weekly subcutaneous injections.

What patients explore it for

Common therapeutic uses and patient goals.

Clinicians and patients most commonly explore GLP-1 receptor agonists for the following indications. Where noted below, uses are FDA-approved; others are off-label and emerging.

Weight Management in Obesity

FDA-approved for adults with BMI ≥30, or BMI ≥27 with at least one weight-related complication (hypertension, dyslipidemia, obstructive sleep apnea, or type 2 diabetes). The most commonly explored primary indication in telehealth settings.

Type 2 Diabetes — Glycemic Control

All agents are FDA-approved for glycemic management in type 2 diabetes. GLP-1 agonists offer glucose-dependent insulin stimulation with low hypoglycemia risk and are often preferred over other agents for their cardiovascular and renal protective profiles.

Cardiovascular Risk Reduction

Confirmed by the SELECT trial: semaglutide 2.4 mg reduced the composite of cardiovascular death, nonfatal MI, or nonfatal stroke by 20% in non-diabetic adults with obesity and established cardiovascular disease — the first weight-management medication to demonstrate CV event reduction in a non-diabetic population.

Non-Alcoholic Fatty Liver Disease

Off-label; an active clinical trial area. Semaglutide and tirzepatide have shown meaningful reductions in hepatic fat in imaging studies, with ongoing Phase 3 trials evaluating histological endpoints in MASH (metabolic dysfunction-associated steatohepatitis).

Body Composition

Improvement in body composition as an adjunct to lifestyle intervention — reducing fat mass while research on lean mass preservation is ongoing. Adequate protein intake and resistance exercise are clinician-recommended accompaniments to GLP-1 protocols.

Pre-Surgical Weight Optimization

For patients who cannot access or are not candidates for bariatric surgery, GLP-1 agonists represent a pharmacological alternative with meaningful evidence. Clinical programs increasingly integrate surgical and pharmacological approaches based on individual patient profile.

Evidence summary

Key clinical trials — all PMIDs verified.

The GLP-1 receptor agonist class has one of the most robust clinical trial programs in recent pharmacology. All citations below are Level I evidence (multi-center RCTs or systematic meta-analyses).

STEP 1 Trial — Semaglutide 2.4 mg

PMID: 33567185 · Wilding et al., NEJM 2021

In this landmark double-blind RCT of 1,961 adults with overweight or obesity without diabetes, once-weekly subcutaneous semaglutide 2.4 mg produced a mean body weight reduction of 14.9% versus 2.4% with placebo at 68 weeks. A total of 86.4% of semaglutide-treated participants achieved ≥5% weight loss; 50.5% achieved ≥15% weight loss. One of the most cited obesity pharmacotherapy trials in history.

SURMOUNT-1 — Tirzepatide 15 mg

PMID: 35658024 · Jastreboff et al., NEJM 2022

In 2,539 adults with obesity or overweight with complications, once-weekly tirzepatide 15 mg produced a mean weight loss of 20.9% over 72 weeks versus 3.1% with placebo (p<0.001). At the highest dose, 57% of participants lost ≥20% of body weight — the largest weight reduction ever observed in a Phase 3 pharmacotherapy trial at time of publication. GI adverse events were the most frequent but generally mild-to-moderate and transient.

SELECT Trial — Cardiovascular Outcomes

PMID: 37952131 · Lincoff et al., NEJM 2023

In 17,604 non-diabetic adults with obesity and established cardiovascular disease, semaglutide 2.4 mg reduced the composite of CV death, nonfatal MI, or nonfatal stroke by 20% (hazard ratio 0.80, 95% CI 0.72–0.90; p<0.001) over approximately 40 months. First demonstration that a weight-management medication reduces cardiovascular events in a non-diabetic population — fundamentally changing how obesity is framed as a cardiovascular risk factor.

SURMOUNT-4 — Withdrawal Trial

DOI: 10.1001/jama.2023.24945 · Aronne et al., JAMA 2023

Discontinuing tirzepatide after 36 weeks led to a mean weight regain of ~14% over the subsequent 52 weeks, while those who continued achieved cumulative weight loss of 25.3%. This finding underscores the chronic disease model: weight regain upon discontinuation is not a treatment failure but an expected pharmacological consequence of stopping a medication that addresses an ongoing physiological condition.

Meta-Analysis — Semaglutide Without Diabetes

PMID: 38643122 · Moiz et al., Am J Cardiol 2024

Pooling 4 RCTs (n=3,087), semaglutide was associated with a 12.1% relative body weight reduction and a 12.3 kg absolute reduction versus placebo over ≥68 weeks. Gastrointestinal adverse events occurred more frequently with semaglutide (RR 1.47), though most were transient. Provides meta-analytic confirmation of the STEP program findings across study populations.

Dosing context — educational only

What clinical titration protocols look like.

⚠ EDUCATIONAL ONLY — Not a Prescription

The dosing information below describes published clinical trial and FDA-approved label protocols for context and education only. It does not represent a prescription, recommendation, or individualized dosing guidance. All dosing decisions are made exclusively by a licensed prescribing clinician based on your individual health history, lab values, current medications, and clinical assessment. Do not adjust or initiate any medication based on this information.

Semaglutide — Standard Titration

FDA-approved obesity indication (Wegovy®): begins at 0.25 mg once weekly for 4 weeks, titrated upward over 16–20 weeks through 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg maintenance dose. Titration is designed to minimize GI tolerability issues. Some patients are managed long-term at sub-maximal doses based on tolerability or clinical response. Dose forms: prefilled subcutaneous autoinjector pen.

Tirzepatide — Standard Titration

FDA-approved obesity indication (Zepbound®): initiation at 2.5 mg once weekly for 4 weeks, then 5 mg; further dose escalation in 2.5 mg increments every 4 weeks as tolerated, up to a maximum of 15 mg weekly. The SURMOUNT trials used the maximum tolerated dose. Dose forms: prefilled autoinjector pen.

Safety & contraindications

What you need to discuss with your clinician.

GLP-1 receptor agonists are prescription medications with real risk profiles. This is a general educational summary — your clinician evaluates your individual history.

Absolute Contraindications

Personal or family history of medullary thyroid carcinoma (MTC). Multiple Endocrine Neoplasia type 2 (MEN2). Known hypersensitivity to semaglutide, tirzepatide, or any excipients in the formulation. Pregnancy (use effective contraception; discontinue before attempting conception per prescribing label).

Common Adverse Effects

Nausea, vomiting, diarrhea, constipation — typically most prominent during dose escalation and resolving in most patients with continued use. Injection site reactions (occasional). Increased resting heart rate (+2–4 bpm; clinical significance uncertain in most patients).

Important Cautions

Pancreatitis: rare association; patients with a history of pancreatitis should discuss risk-benefit with their clinician carefully. Gastroparesis/delayed gastric emptying: may affect absorption timing of other oral medications (e.g., oral contraceptives, levothyroxine). Gallbladder disease: increased risk of cholelithiasis with rapid weight loss.

Monitoring Considerations

Diabetic retinopathy: rapid glycemic improvement may transiently worsen pre-existing retinopathy — ophthalmology evaluation recommended. NAION: observational signal in some populations; absolute rates low in RCTs. Renal function: GI fluid losses warrant hydration monitoring. Drug interactions: gastric slowing may affect narrow-therapeutic-window oral medications.

Regulatory status — May 2026

FDA approval, compounding rules, and what changed.

FDA Approval Status

Semaglutide: FDA-approved for type 2 diabetes management (Ozempic®, 2017; oral Rybelsus®, 2019) and chronic weight management (Wegovy® 2.4 mg, 2021). The FDA shortage list designation was resolved in early 2025 following Novo Nordisk's affirmation of adequate supply.

Tirzepatide: FDA-approved for type 2 diabetes (Mounjaro®, 2022) and chronic weight management (Zepbound®, 2023). Removed from the FDA drug shortage list in late 2024/early 2025.

503A Compounding Status

With shortage designations resolved, the broad legal basis for compounding semaglutide and tirzepatide under 503A has substantially narrowed. The FDA issued clarifying guidance (April 1, 2026) reminding 503A compounders that compounded drugs may not be essentially copies of commercially available products absent a specific patient need. On April 30, 2026, the FDA also proposed to formally exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list.

503A carve-outs that may remain valid (consult a healthcare attorney): documented allergy or hypersensitivity to specific brand-product excipients; need for a dose or formulation not commercially available; specific individualized patient-needs as documented by the prescribing clinician. This is a rapidly evolving regulatory area requiring real-time legal and compliance guidance.

For a detailed side-by-side comparison of compounded versus brand-name semaglutide — including the full regulatory timeline, pricing, safety data, and questions to ask your clinician — see our Compounded vs. Brand Semaglutide comparison page.

FAQ

Common questions about GLP-1 receptor agonists.

How much weight can I expect to lose?

Clinical trial data suggest semaglutide 2.4 mg may support approximately 15% average body weight reduction over 68 weeks; tirzepatide may support 15–21% depending on dose. Individual results vary significantly based on adherence, lifestyle, starting metabolic health, and genetic background. These are population averages, not guarantees for any individual patient.

Will I regain weight if I stop?

The STEP 1 extension and SURMOUNT-4 trials demonstrate that approximately two-thirds of lost weight returns within 12 months of discontinuing treatment. GLP-1 agonism treats a chronic physiological condition — ongoing treatment is generally required to maintain benefits, similar to blood pressure or cholesterol medications.

What's the difference between semaglutide and tirzepatide?

Semaglutide activates only the GLP-1 receptor. Tirzepatide activates both GLP-1 and GIP receptors, with meta-analyses and head-to-head data through 2025 suggesting slightly greater average weight loss for tirzepatide. Both are clinically meaningful. Individual response varies, and cost, insurance coverage, and side-effect profile all factor into the clinical decision.

Are these safe long-term?

The SELECT trial followed patients for nearly 4 years with a favorable safety profile and demonstrated a cardiovascular benefit. Long-term data beyond 5 years are still accumulating. Both medications carry real risk profiles and absolute contraindications that require clinician evaluation. They are not appropriate for casual or unsupervised use.

Is compounded semaglutide still legal in 2026?

Compounded semaglutide as an essentially equivalent copy of Ozempic or Wegovy is no longer broadly legal since the shortage resolved in February 2025. A narrow 503A pathway remains for individualized patient needs with prescriber-documented clinical rationale. Cost savings and patient preference alone do not qualify. See our comparison page for full detail.

What if I experience nausea?

Nausea is the most common adverse effect, typically most pronounced during dose escalation. Smaller meals, lower-fat foods, adequate hydration, and consistent injection timing may help. Persistent or severe nausea warrants a conversation with your prescribing clinician — dose adjustments or slower titration are often available and effective.

Informational only. Content on this page is for informational purposes and does not constitute medical advice. All prescriptions are issued at the sole discretion of the prescribing clinician. GLP-1 receptor agonist prescribing requires a complete clinical evaluation. Not all formulations are available in all states. Individual results vary. Last reviewed: May 2026.

Compounded vs. Brand Semaglutide

Full regulatory timeline, side-by-side comparison table, red flags checklist, and 10 questions to ask your clinician. Updated for the 2025–2026 regulatory landscape.

Read the Comparison

GH Secretagogues

CJC-1295, ipamorelin, sermorelin, tesamorelin, and MK-677 — how growth hormone secretagogues work, what tesamorelin's Phase 3 evidence shows, and the regulatory landscape as of mid-2026.

Explore GH Secretagogues

Start a Clinical Evaluation

A licensed clinician reviews your health history and determines whether a GLP-1 protocol aligns with your individual goals and clinical profile.

Start Your Intake

GLP-1 Receptor Agonists